Overview

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Boehringer Ingelheim
Treatments:
Duloxetine Hydrochloride
Gabapentin
gamma-Aminobutyric Acid
Pregabalin